Skip to main content
Premium Trial:

Request an Annual Quote

Unilabs to Develop Companion Dx for Biogen Idec Drug

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Unilabs will develop a companion diagnostic assay for a Biogen Idec drug for patients receiving a multiple sclerosis treatment, the Copenhagen-based firm said today.

Under the agreement, Unilabs will develop a two-step ELISA test to detect anti-JCV antibodies to help stratify patients receiving Biogen Idec's Tysabri (natalizumab). The presence of anti-JCV antibodies is one of three risk factors, along with prior immunosuppressant use and treatment duration, used to calculate the risk of Tysabri-treated patients developing progressive multifocal leukoencephalopathy.

The firms have also developed a closed web interface to allow neurologists to order sampling and shipping materials, register sample pick-up details, and request language and format of analytical reports.

Further terms of the collaboration were not disclosed.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.